Ascendis Pharma A/S
TransCon CNP
achondroplasia
Resolved
180days ago
Phase 2 readout · Jan 8, 2026
What's at stake
Phase 2 trial results for TransCon CNP in achondroplasia are due Jan 8, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 15h ago
“On January 8, 2026, the Company announced topline results from Week 52 of COACH, the first Phase 2 clinical trial to evaluate combination therapy with once-weekly TransCon CNP (navepegritide) and once-weekly TransCon hGH (lonapegsomatropin)”